Physician profile
Mary Evans
NPI 1760143747
$6,751.46
in general payments reported to CMS, 2019-2025
21 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,097 · 2023: $3,048 · 2024: $2,492 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,607 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,607.46 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,024.68 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $779.72 | 2022-2024 | Caplyta |
| Corium, LLC | $631.27 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $592.45 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $389.92 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $346.04 | 2022-2024 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $311.01 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $297.33 | 2022-2024 | Spravato |
| Alkermes, INC. | $272.32 | 2022-2024 | Aristada, Lybalvi |
| Neos Therapeutics, Lp | $268.87 | 2022-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Lundbeck LLC | $159.39 | 2022-2024 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $157.32 | 2023-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $134.29 | 2023-2024 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $126.92 | 2024 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $93.69 | 2022-2024 | Uzedy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $74.82 | 2024 | |
| Vertical Pharmaceuticals, LLC | $30.74 | 2024 | Relexxii |
| Alfasigma USA, INC. | $19.21 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.78 | 2023 | Quviviq |
| Bausch Health US, LLC | $16.31 | 2023 | Aplenzin |
| Channel Medsystems, INC. | $8.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.